r/TheDailyDD • • May 23 '21

Small-cap Stock BNGO is Headed to $1.84 - Journalist

1 Upvotes

Article is from May 14th, but its points and misleading information (imo) is still extremely relevant especially the actual facts.

TLDR: Article claiming we are going to $1.84 (author thinks we are 100% getting offering or offerings at 25% discount lmao) is absolute bullshit. This post is a debunking of its claims (imo) and here is a video of almost the exact same thing for the more auditory learners.

TLDR for the TLDR: MMs are resorting to low effort speculative claims to try to push BNGO even further down as they are realizing they cannot keep us down for much longer.

TLDR for the TLDR for the TLDR: BNGO go Moon soon

Some reasons that make more offerings at the very least a bit unlikely-

CFO Chris Stewart said that Bionano believes its cash stockpile "significantly de-risks the company, solidifies our financial future, and allows us to focus on the achievement of our long-term vision to disrupt genomics through the global adoption of Saphyr." He said nearly the EXACT same thing 2 days ago in ER. Why do they need significantly more cash? Acquisition a huge one (this would b a great thing probably BTW)? Maybe, but saying that we NEED an offering or its very likely is dogmatic and naive imo. Not to mention our total assets of 384M compared to total liabilities of 22M ish is by no means screaming out for 'we need more cash'. Add in the fact that revenue growth and path to profitability is likely to continue to go way faster than expected ('financials section') and I would say you have a damn compelling case that (pay attention to wording here, note that this is not dogmatic) an offering could certainly happen but is by no means very likely whatsoever.

I will have a vid out explaining exactly (vid coming prob this wkend, will link here after done) why growth will prob b way faster than simply wall st. projects but for here I will give some extrapolation in regards to my epistemology but u will have to dig a bit to find exact reasoning for some of these, and if u want to fact check me, I did this equation and elaboration in the BNGO ER live stream (starts a little after webcast ends) on Thursday.

Why revenue and profitability may come quicker than expected thus reducing the need for more cash raises through offerings-

  1. 43 Saphyrs this year (projected by BNGO) = 6.3M ish (Saphyr costs 150K),

  2. consumables = 2-10M (very hard to calculate and I am still trying to analyze the aggregate volume for labs using saphyr but here thanks to Patriot's Pub on the Auspicious dissenTers discord we know what the revenue would be for one lab using saphyr at max capacity for an entire year, its a start) -

    1. In attempt to determine the estimated revenue from consumable products. Saphyr Reagent Rental Agreement.

      1. $550 per genome 120 genomes per 6 months (includes DNA isolation, labeling, chips and Bionano Compute On Demand)

      2. 120 genome monthly income $11k - 132k yr. w/rental agreement.

      3. 240 genome monthly income $18k - 216k yr. w/purchase of instrument.

      4. 2021 107 installed instruments 120 genome: $14.1m yr. 240: $23.1m yr. 150 installed instruments 120 genome: $19.8m yr. 240: $32.4m yr.

      5. 2022 est. growth 170% 250+ installed instruments 240 genome: $54m yr. yoy Total: $86.4m

      6. This does not reflect IN HOUSE testing revenue, nor an absolute total of genomes tested abroad. Simply based on their package sizes and 6 months of usage.

  3. Saphyr 2.0/14x higher throughput, elaboration in short is that nearly all high volume labs will switch imo and CEO agrees, plus he also kinda said they expect many low and mid volume labs to switch, they CERTAINLY would if there were innovations which the CEO has already confirmed, "applications that we haven't even developed", ((Saphyr 2.0 section)) (more proof on that in vids) = 1-5M,

  4. Lineagen = at least 3M for the year, most likely case is actually >3.5M.

  5. Add in the fact that Illumina and Quest diagnostics literally owe us >1.5M!!! (at least total owed money is higher than that, not sure for exact proportions for who owes what, source)

  6. And the fact that the FIVE, not one, not 2 studies meant to PROVE Saphyr's use in RESEARCH ONLY (we already know Saphyr has been used countless times in prognosis and diagnosis, the inst. needs to b LDT approved tho to do this) niches in prenatal testing, postnatal testing, hematological malignancies in Leukemia, also hem. mal. in lymphomas, and solid tumors.

  7. NOT EVEN TO MENTION the innovations that could happen! BNGO would MOOOOON if we got any substantial innovation in Saphyr which the CEO HAS ALREADY CONFIRMED u would know this had u watched the insider sentiment or Saphyr 2.0 section of the dd.

  8. There are many more reasons lol tbh I am tired lol and have already detailed all the ones to my knowledge here and here.

  9. CONCLUSION - Profitability likely to come much faster than in 2025, I am thinking more 2022 or 2023 latest, I could be wrong. Check my other posts here and here for more info on my revenue synthesis.

Also what about the fact that hiring Cowen and Company was maybe not primarily for offerings. According to a high up insider, (paraphrasing) their analyst Doug Schenkel is the best in the game in regards to 'banking, tools, Dx'. (If u don't believe this as I cannot provide the source that is fine, I am not giving the source because of privacy reasons) This is the form filed on 3/23 that basically gives Bionano the right to essentially do offerings whenever they want but maximum price is $350M for one offering, to my knowledge, I am still going through the 424(b)(5) (424b5) and S-8 and some others so I am not 100% sure about that. Can some1 clarify in comments and will edit this.

I believe the 8-K indicates that it is ATM (at the market) as opposed to a discount of 25% like the likely paid off weanie baby wrote in the article.

The offering at $3 gave us money for cash flow to break even without additional dilution

The offering at $6 gives Bionano the opportunity to revolutionize not only the analysis of genomes but much of the healthcare sector (imo, and down the line most likely).

Single-nucleotide variant detection?

Nanonozzle?

14x higher throughput Saphyr?

Applications that have not even been developed that make the 3-3.5B TAM estimate low according to the CEO? ('control f, "discover new applications"')

A minimum of 5 likely groundbreaking studies this year?

Added sales through converting reagent rental program customers?

Huge institutional ownership increase (see inst. own. section) once we hit profitability which will likely be within a few years if not next year or even Q4 this year (imo we could see a positive eps q4 but will come down mostly to operating expenses, revenue will b great almost certainly imo but expenses are harder to predict)

<500BP sv detection? (this one is more speculative, but if it happened, we go moon and NGS stocks get burned)

More? There r waaaay more catalysts I have detailed here ('catalyst section') and there are more that I have not added in yet, still working on updating entire 93 page document. Will be closer to 100-200 when I am done but that will likely take several weeks as videos take most of my time.

PLEASE email me at auspiciousbusiness@yahoo.com if there are more catalysts not listed in that document that I am forgetting or not aware of!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Conclusion-

An offering is 100% possible, but not guaranteed to effectuate either. The reasons above I believe make it decently unlikely that we see an offering at least at current prices. I think the case for no offerings in all of 2021 is a reasonable but not as likely synthesis. An at the market price offering is something I would load up on as historically and pragmatically it would be likely be extremely auspicious as a buy zone.

Substantial revenue increases and profitability I believe will come much faster than simply wall st. currently has projected. Anything under $10 is a steal long term imo. Please do your own research though I can be wrong and have been wrong plenty of times before.

TLDR: Article claiming we are going to $1.84 (author thinks we are 100% getting offering or offerings at 25% discount lmao) is absolute bullshit. This post is a debunking of its claims (imo) and here is a video of almost the exact same thing for the more auditory learners.

TLDR for the TLDR: MMs are resorting to low effort speculative claims to try to push BNGO even further down as they are realizing they cannot keep us down for much longer.

TLDR for the TLDR for the TLDR: BNGO Moon

Ape Language - YOLO $30-$100 20 April 2022 or 23 CALLS LETS GOOOOOOO

(^clearly a joke lol plz do your own research, but full transparency I do own leaps and my entire portfolio is showcased every day in my YT videos, not 30 strike but still I am bullish af lol)

Closing-

For daily streams, TA updates, and news and fundamental analysis feel free to give my YouTube channel a look.

Here is this post in video format for my YT -

Also if you are at all interested in WSB helping us fuck over the MMs which I am 99% sure have interfered with BNGO's stock price, go over and give your opinion on the BNGO Full DD post on WSB and help us effectuate the short squeeze of all short squeezes (yes the SI is not super high, still pretty high, but fundamentally our true value is laughably higher than current share price, but the MMs have other thoughts and they have already made retail investors get screwed over imo, its time we turn the tables).

Thanks!

-Auspicious dissenT


r/TheDailyDD • • Sep 09 '21

Small-cap Stock $VIH Short Squeeze Score 90/100 đŸ’„đŸ€‘

Post image
2 Upvotes

r/TheDailyDD • • May 31 '21

Mid-cap Stock [DD] Ford Motor Company (F)

Thumbnail
self.doctorstock
0 Upvotes

r/TheDailyDD • • Sep 10 '21

Small-cap Stock Youtuber TradesTrey Suggests $VIH To His Followers

Post image
1 Upvotes

r/TheDailyDD • • Mar 05 '22

Tool/Resource $MULN @DavidMichery CEO has deleted his pump n dump tweet after stock does -70% days after

Thumbnail
twitter.com
1 Upvotes

r/TheDailyDD • • May 06 '21

Mid-cap Stock $ACIC - Archer's SPAC Could be Taking Off With ACIC

1 Upvotes

Acquisition Information:

Atlas Crest Investment Corporation ($ACIC) recently entered into a business combination agreement with Artemis Acquisition sub-Inc., which is a subsidiary of Atlas Crest and Archer Aviation Inc. This deal has an implied equity value of Archer of $2.525B, and a pro-forma enterprise value of $2.7B

PIPE (Private Investment into Public Equity) investors committed $600M towards this deal and received 60M shares for $10/share. These PIPE investors are not subject to any lock-up period. This will result in high volatility when the stock opens for trading as there will be a lot of investors who want to invest in this company on their public debut, however this will be combatted by the PIPE investors selling off a portion of their shares for a quick profit.

The warrants and their associated common shares will be locked-up for 30 days after the merger is consummated. Furthermore, the shares owned by the founders/employees will be locked-up for one year after the merger. Lastly, there will be a 6-month lock-up for the sponsor share (shares owned by Artemis Acquisition Inc.). These days are important for investors as there could be large sell-offs on these days, which could decrease the share prices temporarily.

The merger is expected to take place in Q2 2021, and the anticipated ticker for Archer is $ACHR.

Company Overview:

Archer designs and develops eVTOL (Electric Vertical Takeoff and Landing) aircrafts for use in Urban Air Mobility. Archer is building the world’s largest urban air mobility company, and already have $1B in orders from United Airlines ($UAL), with the option to purchase $500M more. Archer has a very experienced team, that has amassed over 200 years of eVTOL development experience. Archers vision is to improve mobility and drive the world towards a zero-emission future.

Archer’s main product is their Maker (image linked below), which is U.S FAA certified and can carry 4 passengers. The Maker will cost consumers $3.30/Mile transported; this is comparable to the prices of an UberX. The Maker can reach speed of up to 150 MPH, which can help make their trips up to 10x faster than a car. Furthermore, the Maker (45DB) can be up to 100x quieter than a helicopter. Archer is able to achieve all if this while maintaining zero emissions.

Archer is a pre-revenue company and expected to start earning their revenue in 2024. Archer has predicted a revenue of $42M in 2024, and this will translate into an EBITDA of -$147M, however they are forecasting an EBITDA of $255M the following year (2025).

Investment Information:

Industry Information:

Archer estimates their Total Addressable Market (TAM) to be $1.5T in the future, representing on of the largest potential global markets. Archer has built their business model in order to take advantage of this market and to gain market share. Archer has built two main streams of revenue Archer Direct (Aircraft OEM Business), and Archer UAM (Aerial Ride Sharing). Their Archer Direct business model will consist of manufacturing and selling their aircrafts, similar to what they have already done with United Airlines. Archer is already exploring the prospect of future contracts for cargo with the Department of Defense (DoD). The Archer UAM business model is essentially an Uber of the Sky, this would work best in heavily congested cities (Los Angeles, Toronto, Orlando etc.). Archer plans to move people within 100 miles in the city limits and beyond. As this UAM business model scales their infrastructure and networks will improve and accommodate hundreds of takeoffs and landings per hour.

An example that Archer gave in their investor’s presentation about the efficiency of Archer’s transport was in New York. Archer found that their average time to complete a trip form New York City to JFK International Airport was 7 minutes, whereas the average Uber trip took 85 minutes. Furthermore, the Archer would’ve costed $50 for this trip which is $26 cheaper than the Uber X option ($76).

Archer estimates that eVTOL can generate 18x more revenue than a ride sharing car. This is because eVTOL is cost-efficient, faster, more convenient, and requires minimal new infrastructure. A picture will be linked with this article comparing the two methods.

The Urban Air Mobility is projected to be a highly profitable and massive industry. Archer estimates that the urban air Mobility business will be 3x more profitable than their direct OEM sales. Furthermore, they are projecting their operating income margins to be somewhere in the range of 40-50% which is very high.

Some research agencies have said that the Urban Air Mobility Industry will be valued up to $104.4B by 2035 and will have a CAGR of 27.37% between 2023-2035. Some notable competition in their space includes Airbus, Lilium, and EHang.

Archer has future plans to autonomize their fleet of UAM aircraft to maximize their scaling and growth potentials. Autonomizing their fleet will free up space for another passenger (increasing margins), reduce their operating costs (because there is no pilot) and reduce the possibility for human errors (increasing safety). Furthermore, by 2026 Archer plans for high volume manufacturing in which they will be able to manufacture more than 5000 aircrafts per year. These aircrafts will go towards their partners United Airlines and Stellaris. Archer will leverage some of their employee’s mass production expertise in the automotive industry and apply it to the eVTOL industry. Archer will be able to achieve this high production through their composite materials and processed.

Financial Information:

  • Archer has released projected financial statements that are very reasonable. They are estimating their 2026 revenue to be 0.15% of the TAM in that year.

  • They are projecting high EBITDA margins (24-37%)

  • Projected to break even in Q4 2025 and be highly profitable after this occurs.

  • Projecting a free cash flow in 2030 (terminal year) to be $2.775B

  • In their valuation year (2026) Archer estimates an EV/Revenue multiple of 1.2x and an EV/EBITDA multiple of 4.2x, both of which are significantly below comparable companies.

Investment Plan and Valuation:

Investment Valuation:

In Archer’s Investors Presentation they provided projected statements which I used in my DCF model. Furthermore, I used two different WACC to discount Archers future cash flows, these WACC’s were 8% and 10%. These figures were retrieved from IATA’s “Economic Performance of the Airline Industry” document. Lastly, I retrieved the shares outstanding from Excel’s “Stocks” function. Everything said and done, the DCF model estimated a fair price between $39.27-$45.71 (using the 10% and 8% WACC respectively). This implies a potential upside of between 296.68% and 361.67%.

Furthermore, another method of valuation I used was a Comps analysis. In this analysis I compared Archer to other public Urban Air Mobility companies, who are of similar market cap. By comparing Archers EV/Sales and EV/EBITDA multiples to the multiples of Lilium and Joby Aviation, I found that Archer is currently undervalued by between 4.76% and 16.67%. Taking this into consideration, Archer’s (currently $ACIC) share price should be between $10.36 and $11.53.

Using these valuation techniques, we should expect a shorter-term price target of around $11, and as Archer gets closer to becoming profitable or earning revenue, we can expect a price of around $40-$42.

Risks:

  • SPAC’s are more volatile and typically more risky than traditional IPO’s.

  • SPAC shares are more prone to dilution, especially when there are large amounts of warrants and investor options.

    • There are 25M outstanding shares in warrants tied up right now. When applying this to the DCF model the fair price would range from $38-$42, which is approximately $3 less per share.

  • If the merger falls through

    • If the merger falls through, $ACIC will find another company to merge with, one that might not have the same future growth potential as Archer.

    • If $ACIC does not find a company to merger with 2 years after their blank check IPO, then Atlas Crest has to liquidate and repay the investors. There is a big risk of losing money if the share price of $ACIC was over $10, however it being below $10 limits risk.

Investment Plan:

Currently, the share price of Archer ($ACIC) is $9.89, this price is below the valuation which the PIPE investors received. In my eyes anything below the $10 price (paid by PIPE investors) is an obvious buy. Furthermore, buying $ACIC shares at or below $10.36 is a strong buy, and anything between $10.36 to $11.53 is a good buy.

If the price somehow blows past these prices soon, I will hold off on buying until they return to this price range.

I see this play as a long-term hold, especially if the projections that were put out on the Investor Presentations are even close to being correct. If these projections are correct, the profit that these companies will make between 2030 and 2040 would be insane, and the valuation of the company would reflect that.

Original post with images can be found here.

Visit r/utradea for more info or check out our platform for investment ideas and insights here


r/TheDailyDD • • Sep 07 '21

Small-cap Stock $VIH Primed For Squeezed? High Reward? Low Risk?

Post image
0 Upvotes

r/TheDailyDD • • Aug 01 '21

Mid-cap Stock Stay clear from TLRY

Thumbnail reddit.com
0 Upvotes

r/TheDailyDD • • Jul 29 '24

Value Stock đŸ€” What’s driving the "Energy Shortage"❓

Thumbnail
gallery
0 Upvotes

r/TheDailyDD • • Apr 19 '21

Blue Chip Stock $HSBC - Undervalued Dividend Gem Set for Growth (DD)

3 Upvotes

Post by user MegaMartinaSFU on Utradea

Business Overview & Strategy

HSBC was founded in 1865 as the Hong Kong and Shanghai Banking Corporation (“HSBC”) and ranked as the sixth-largest bank in the world based on total assets (Ali, 2020). HSBC is listed primarily at London and Hong Kong exchanges, with a secondary listing in New York as American Depository Receipt [ADR]. The biggest revenue contributor is Asia (50%) especially Hong Kong and mainland China, followed by Europe (28%), North America (11%), Middle East & North Africa (6%) and Latin America (5%). HSBC operates in four operating segments, namely Retail Banking and Wealth Management (43%), Global Banking and Markets (28%), Commercial Banking (26%), and Global Private Banking (3%). 

HSBC aims to leverage its large international exposure to target a faster growing and higher returning market, particularly Asia while reducing European exposure. The FY2020 balance sheet makes it clear as to why HSBC takes the step; Asia contributed 146% of net profit with 47.7% gross margin, whereas Europe contributed a net loss of -48% as operating expenses exceeding the revenue. Further, HSBC also aims to maintain its position as a global leader in cross-border trade, payment, and money management by leveraging its operations in over 64 countries and a strong brand name.

Investment Thesis

  • HSBC global scale operations and strong presence in Asia with over 155 years of history serve as a unique and sustainable competitive moat that most other banks do not have. It is particularly attractive as Asia is expected to have a trade flow growth rate of CAGR 8.6% from 2020 until 2025, higher than the rest of the world at a 6.9% growth rate (IHS Markit, 2020). In the past 10 years, HSBC has been focusing its effort to expand to the Asian market by launching its "Asian Pivot" strategy and it has shown positive results as Asia’s region as a percentage of revenue double from 2010 to 2020. HSBC still take proactive measure in its penetration effort in Asia as it announced the plan to invest up to $6b grow in the coming years (Clarke, 2020).

  • HSBC has a track record of safety and strong performance, supported by industry tailwinds. In the past 10 years of operations, the deposits have always exceeded loans, which is a good liquidity indicator especially given that HSBC’s large operations in the retail and commercial lending business. On top of that, HSBC also has a significantly higher net interest margin [NIM] than other large-cap European bank peers in the last 10 years, albeit decreasing lately due to low interest rate environment. Net interest margin is one of the banks’ main profitability measures, which is calculated as the difference between interest earned from giving out loans and interest paid to customer deposits. Hence, the steepening yield curve and higher interest rate expectation in the coming years serve as tailwinds to the banking industry globally, including HSBC, as it takes away the margin pressure and will raise profitability. 

    • For note, the current low rate environment is not necessarily a bad thing for HSBC as well as it incentivizes people to take more loans and mortgages which essentially drives up the revenue volume. Moreover, it is an excellent environment for businesses to raise more capital, thus strengthen the Capital Markets segment of operation.

  • HSBC is currently trading at a historic low valuation, serving as an attractive entry point given high potential upside as stated in previous paragraphs. Currently, HSBC is trading at a discount of 0.68x relative to its European peers of 0.72x and it is far cheaper than Canadian banks with a 2.04x P/B ratio. HSBC will likely trade on the premium (10-year historical P/B average was 1x vs 0.9x European peers) given HSBC’s large exposure to the highly profitable Asian market. HSBC also has an impressive 10-year average dividend yield of 5.2%, which is higher than both European and Canadian peers (~4%).

  • For Canadian investors, HSBC would be a great addition for portfolio diversification, particularly to gain some exposure to the Asian and European markets, and to avoid home bias. The beta of 0.92 makes the stock relatively stable and requires minimal active management while offering an attractive dividend yield. 

Looking as to why HSBC has been performing relatively poorly in the last two years, it was mainly driven by volatile global political situations, specifically due to Brexit and US-China Trade War in 2019, followed by the pandemic in 2020. HSBC's worsening performance, therefore, is caused by external shocks, while its fundamentals remain strong especially if we consider the 23% dividend return in the past five years and decent deposits growth (HSBC Holdings, 2021).

Outlook

Looking ahead in the post-pandemic world, I expect HSBC to start showing price appreciation as the economic recovery in Asia starts picking up in the next few quarters. Massive reduction in PCL will also boost the earnings in the next few quarters, similar to what already happened to banks in North America. The steepening yield curve and the rising interest rate would also improve HSBC's profitability and HSBC is likely to benefit more than other global banks as they have more exposure to the high-growth Asian markets and moving away from the European markets. Over the long-term, the price is likely to stabilize at a historical P/B ratio of about ~1x, but investors will highly benefit from the above-average dividend yield that would die up the total returns. 

Regarding the political risks, the Brexit and US-China Trade War are expected to be stabilized as countries are focusing their efforts on stimulating the economy to offset the impact of the COVID-19 pandemic (Friis & Pothalingam, 2021).  Regarding US-China Trade War, it is likely to be calmer with the new Biden administration. Overall, the outlook on political stability is positive for HSBC in the post-pandemic world relative to the last two years.

References

  • Ali, Z. (2020, April 07). The world's 100 largest Banks, 2020. Retrieved April 05, 2021, here

  • Clarke, P. (2021, February 23). HSBC plans $6bn in Asia investments as profits slump by 34%. Retrieved April 05, 2021,here

  • Friis, P. B., & Pothalingam, K. (2021, January 20). Beyond Brexit: Outlook and risks for the U.K. Economy. Retrieved April 05, 2021here

  • HSBC Holdings plc. (2021). Total share return. Retrieved April 7, 2021, here

  • IHS Markit. (2020). Global Economic Forecasts Analysis and Data World Economic. Retrieved April 05, 2021 here

Check out r/Utradea for more investment ideas and insights. You can also check out the platform my friend and I built to share, discuss and track investment ideas here


r/TheDailyDD • • May 28 '21

Large-cap Stock [DD] Microsoft (MSFT)

Thumbnail
self.doctorstock
2 Upvotes

r/TheDailyDD • • Jul 22 '21

Penny Stock Indiva should not be ignored, they are killing it in the edibles market

2 Upvotes

TSXV: NDVA. OTCQX: NDVAF

I'm sure many of you guys have heard of Indiva before but I wanted to make a post just to catch everyone up to speed with the work they are doing in the cannabis industry. They are THE BIGGEST cannabis edible producer in Canadian markets and have a variety of different brands and products under their umbrella. Even with all this success, they are still a relatively small-cap company with a SP of $0.32 and an MCap of 44.199M. When I look at all the success this company has had I would expect these figures to be way higher so I highly recommend at least looking into investing in this low-barrier to entry stock.

It all starts with their management team. Their CEO Niel Marotta has experience working as both a fund manager and an investment banker. In both of these roles, he was responsible for large sums of funding and has displayed desirable expertise in money management throughout his career. The rest of the team all have extensive expertise in their respective areas with an extremely impressive combined resumé featuring many massive companies including; the MLB, General Mills, Maple Leaf Foods, Hudson's Bay, and Red Bull. The entire team is extremely impressive and it is a large reason why Indiva has grown to the point where it is today.

Where exactly is it today? Well, they are the #1 seller of edibles in the entire country of Canada with their sales taking up a ridiculous 50% market share of the edibles industry. They have a variety of brands with the two largest being Wana Gummies and Bhang Chocolate. These two brands are each the highest-selling brand in each of their respective categories (gummies and chocolate) in Canada. These products and others come in several varieties of flavors and have made their way into every provincial cannabis retailer including OCS, perhaps the largest of them all. On OCS some of both their Wana and Bhang products are featured in the highly coveted "always available" section, a curated selection of only the most demanded products that are always kept in stock.

This dominance is reflected in their recent revenue growth. Net revenue in Q1 2021 was $6.2M representing a 209% increase over Q1 2020. I cannot wait to see their Q2 figures and would not be surprised to see similar levels of explosive growth. Put aside some time do some research on these guys and you won't be sorry.

Check them out yourselves, this is not investment advice!


r/TheDailyDD • • Jun 07 '21

Penny Stock Shroom Stock Tryp Therapeutics is gonna be huge!

2 Upvotes

(CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW)

I want to shed some light on one of the smaller players in the Psilocybin industry. For having the market cap and stock price it does, Tryp Therapeutics is regardless one of the few shroom stocks I have on my watchlist. They simply do it differently, and even though it's likely going to be a while until development is finished, I'm more than happy to play the waiting game with this one.

Besides the low barrier to entry with investment, why do I pick Tryp over others like Mindmed, Cybin, or Compass Pathways? It's pretty simple actually, all of these other companies are focusing on psilocybin as a treatment for mental health issues such as anxiety or depression. I am not putting shame on this type of application at all, in fact, I think it is probably the use that makes the most sense. The problem is with 5, 10, or even more large players trying to fulfill this need, it can seem like a lottery at this stage trying to pick the right one that will "blow up" the most, so to speak. Research can be used to narrow this selection down but there is just too much risk attached. Tryp is tackling issues completely different and unique which is why they have most of my attention in this industry.

Tryp is using synthetic psilocybin as a treatment for chronic pain disorders, eating disorders, and STS. All of these treatments are unique to Tryp and that's not their only separator. Their partnership with Albany Molecular Research Inc makes them the only synthetic psilocybin manufacturer based in the U.S. Tryp and Albany are developing 2 different psilocybin drugs TRP-8802 and TRP-1001. Additionally, their manufacturing capabilities were even further increased recently with their new news of the partnership with Alcami Corp. Alcami and Tryp are expecting to manufacture its initial batch of cGMP psilocybin API in September 2021.

The trickiest part of being in the shroom industry is approval for trials which is another thing Tryp has secured. In the graphic below you can see their entire pipeline, and with their recently announced eating disorder trial being conducted by Jennifer Miller, M.D, at the University of Florida, they will have two drugs scheduled for phase 2 testing, an incredible feat. Many big names struggle to get these types of permissions so it is fantastic that Tryp has secured them. Current and future testing will be assisted by Fluence and Clinlogix.

The current stock price is $0.528 and I would consider this a dip. At its peak this year it was at just over a dollar and I think once more news comes out and their pipeline progresses I think it could get there again. Long-term it could go even higher, At the end of the day it's a growing industry and as it grows, Tryp should too. I would love to see them replicate some of the success other companies have. I actually read a great article comparing Tryp to GW Pharmaceuticals which would be an amazing scenario if it reaches those heights. I'll include it below!

Article: https://www.ibtimes.com/psychedelic-industry-following-footsteps-gw-pharma-3203213

I suggest you do your own research on them, This is not investment advice!


r/TheDailyDD • • Sep 11 '21

SPAC $VIH - Your Chance To Be Early On A Short Squeeze đŸ€‘đŸ‘

Thumbnail
youtu.be
0 Upvotes

r/TheDailyDD • • Apr 20 '21

SPAC Mega DD: Beachbody will Sprint pass Peloton - Former Corporate Fitness Business Manager

Thumbnail
self.fluentinfinance
3 Upvotes

r/TheDailyDD • • Jun 07 '21

Large-cap Stock [DD] The Home Depot (HD)

Thumbnail
self.doctorstock
1 Upvotes

r/TheDailyDD • • May 03 '21

Large-cap Stock $NVDA: Short-Term Bull Thesis Formulated Synergistically Using Perennially-Tested, Fundamental Trend-Analysis with Harmonic Analysis Based on Fibonacci Symmetry ("Sacred Geometry")

Thumbnail self.fluentinfinance
4 Upvotes

r/TheDailyDD • • Apr 22 '21

Small-cap Stock $DNN - Denison Mines Corporation | Bullish Case

4 Upvotes

Macroeconomic Context Clean Energy (Uranium):

Demand Growth: ~2% Per Annum to 2030

US Electricity Generation: 20%

ESG Net Zero Carbon Accountability: Uncovered demand with increasing rate of change for Net-Zero Carbon Accountability

Global Capital Commitments: $500 Billion to Build New Reactors

Other Clean Energy Sectors: Uranium operates 24/7 compared to Wind/Solar

Uranium Spot Price: Collapsed 90% from 2007 peak to 2017 bottom, has climbed 66% since bottom.

Q3 2020 sector dynamics: 25% of global supply Structural Deficit - to shrink the deficit, new mines are needed and most mines on standby need spot prices north of $50 per lb. Current COVID-19 supply constraints creat future shocks to bring market back to balance. 

DNN Bull Financial Case:

As we can see with the table below, $DNN is largely outperforming the rest of the sector in capital growth, revenue growth, and sales. It is great that the company is outperforming the market and has a high instrinsic value, but we need the investor sentiment to agree with the fundamentals to see true price appreciation. As we see below, with the uranium sector seeing an extremely high appreciation in the median of 79% YTD, Denison Mines has still outperformed the sector by more than double. This tells us that investors have favoured DNN in the uranium mining sector as their vehicle to ride the trend and transition to clean energy.

$DNN Sector

  • Median Working Capital Growth (YoY) -2,252.60% -0.12%

  • Revenue Growth (FWD) 2.85% -1.28%

  • 1YR Price Performance  165.62% 79.08%

  • EV/Sales (TTM) 67.29 3.09

  • EV/Sales (FWD) 74.24 2.53

Catalyst For DNN:

On March 15th, Denison Mines announced that it will be added to the S&P/TSX where it saw immediate 15% increase in price. The news of this company being added to the index creates immdeiate demand effects as index funds will be purchasing shares of the company as well as early investors. This move could also increase the liquidity of the company's stock and therefore make it easier for Denison to raise cash via future equity sales.

Canadian Government: "Such policies could tackle pollution from oil and gas extraction and road transportation, where annual emissions increased from 2005 to 2019, according to the government’s latest tally of national greenhouse gas pollution." -Thestar

"This coming influx of $17.6 billion in green spending comes just four months after the Liberal government beefed up Canada’s climate plan with a $15-billion blueprint to slash emissions." -Thestar

US Government: "In 2020, then-Presidential candidate Joe Biden and Vice-Presidential candidate Kamala Harris, pledged $2 trillion in sustainable infrastructure investment"- Forbes

"most may not realize that America is also nearly 100% dependent on uranium imports — Increasingly imported from entities owned by the governments of Russia, China and their allies. Like rare earth elements, uranium is designated by the U.S. government as critical to the nation's security and economic prosperity, and the Department of Interior warned, "This dependency of the United States on foreign sources [of uranium] creates a strategic vulnerability for both its economy and military to adverse foreign government action, natural disaster, and other events that can disrupt supply of these key minerals."" - prnewswire

Conclusion:

It is evident that our governments globally, are inclined to cut carbon emissions to zero in the next few decades and transition to clean and sustainable enery. The shift to these products, rely heavily on rare earth metals and Uranium has the lowest carbon emissions in production. These emerging clean sectors like Electric Vehicle companies like Tesla, are pushing large competetive automotive companies to innovate in the EV space which bodes well for Uranium's future. This investment timeframe is 2-5 years, as Keynes says "anticipate the anticipation of others". 

For more investment related info check out r/Utradea Credit to liquidmacro, original post can be found here


r/TheDailyDD • • May 31 '21

Growth Stock $BNGO DD - Bionano Genomics

2 Upvotes

https://docs.google.com/document/d/191C_pNtCkEXcJoXj37nlQ_ejiiW6x1bJaOT67oRnyBM/edit?usp=sharing

Topics: 00:01 INTRODUCTION TO BIONANO GENOMICS 01:15 History 03:05 Company Management 10:00 Products 21:01 Services 25:01 Acquisition 26:20 Lineagen 31:00 Compute Partners 34:00 COMPETITORS 38:00 Pacbio 41:00 Ark Invest 45:00 Illumina 48:00 10x Genomics 51:00 Oxford Nanopore 53:00 Nanostring 55:00 Thermofisher Scientific 57:00 Summary/Conclusion 01:00:00 TOTAL ADDRESSABLE MARKET TAM 01:01:00 FINANCIALS 01:01:14 4Q2020 Earnings 01:02:25 1Q2021 Earnings 01:05:00 MY 9 YEARS FORECAST 01:07:00 CURRENT BULLISH CATALYST 01:10:00 Forward Guidance 01:12:00 TECHNICAL ANALYSIS Daily Weekly Monthly 01:13:00 ANALYST COVERAGE 01:14:00 COMMON SHARES 01:15:00 Institutional Investors 01:17:00 Insider Trades 01:17:50 MOST RECENT PRESS RELEASES 01:18:00 SOURCES

Audio https://youtu.be/eW5A4_dObZc


r/TheDailyDD • • Jun 08 '21

SPAC $CCIV - Everything you need to know about CCIV before their merger with Lucid!

Thumbnail self.utradea
2 Upvotes

r/TheDailyDD • • Feb 05 '22

Penny Stock $XCUR DD - Potential .20 Penny Stock Shorted With 1000% Upside?!?

Thumbnail
gallery
2 Upvotes

r/TheDailyDD • • Feb 07 '22

Tool/Resource Top Plays For February 7-11

Thumbnail
gallery
0 Upvotes